Company News

Orthocell Records Seventh Consecutive Quarter of Record Revenue at $3.2m

January 6, 2026
Orthocell Limited (ASX:OCC) has commenced 2026 with another strong result, delivering its seventh consecutive quarter of record revenue.  For the quarter ended 31 December 2025, the Company achieved record quarterly revenue of $3.2 million, representing a 7.0% increase on the prior quarterly record and a 45.2% increase on the prior corresponding period. This outcome reflects a compound quarterly growth rate of 10.4% since Q3 FY24.  Key highlights for the period include:  
  • Continued revenue growth driven by strong performance in established markets, particularly Australia  
  • Meaningful progress in the U.S. commercialisation of Remplir™, including: 
    • A distributor network that now covers 25+ States and 40% of the US population  
    • Submission of 61 applications to hospital Value Analysis Committees (VAC) in progress, of which 23 have been approved, ahead of schedule  
    • Completion of 11 major medical education meetings in key U.S. states introducing surgeons to Remplir’s advanced nerve repair capabilities and clinical evidence supporting improved surgical workflow and patient care 
  • Appointment of a second Canadian distributor, positioning the Company for initial sales in the March quarter FY26 and steady adoption through 2026. 
Orthocell ended the quarter with $49.4 million in cash, no debt, and expects to receive an R&D tax incentive refund of approximately $3.0 million in the March quarter FY26, providing strong financial capacity to support continued commercial expansion.  Orthocell CEO and MD, Paul Anderson, said:   “The seventh consecutive record revenue result for the December quarter is particularly pleasing, driven by strong performance in existing markets and early Remplir unit sales in the U.S. Early U.S. results show our hybrid market entry strategy, combining specialist distributors with internal field leadership, is successful and delivering positive momentum. With the U.S. momentum building and Canada coming online, we see significant upside as we replicate the successful Australia and Singapore approach on a larger scale in the U.S.”  Click to read the ASX release.